Cargando…
Enrichment of mutations in chromatin regulators in people with Rett Syndrome lacking mutations in MECP2
PURPOSE: Rett Syndrome (RTT) is a neurodevelopmental disorder caused primarily by de novo mutations (DNMs) in MECP2 and sometimes in CDKL5 and FOXG1. However, some RTT cases lack mutations in these genes. METHODS: Twenty-two RTT cases without apparent MECP2, CDKL5, and FOXG1 mutations were subjected...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107176/ https://www.ncbi.nlm.nih.gov/pubmed/27171548 http://dx.doi.org/10.1038/gim.2016.42 |
_version_ | 1782467169718632448 |
---|---|
author | Sajan, Samin A. Jhangiani, Shalini N. Muzny, Donna M. Gibbs, Richard A. Lupski, James R. Glaze, Daniel G. Kaufmann, Walter E. Skinner, Steven A. Anese, Fran Friez, Michael J. Jane, Lane Percy, Alan K. Neul, Jeffrey L. |
author_facet | Sajan, Samin A. Jhangiani, Shalini N. Muzny, Donna M. Gibbs, Richard A. Lupski, James R. Glaze, Daniel G. Kaufmann, Walter E. Skinner, Steven A. Anese, Fran Friez, Michael J. Jane, Lane Percy, Alan K. Neul, Jeffrey L. |
author_sort | Sajan, Samin A. |
collection | PubMed |
description | PURPOSE: Rett Syndrome (RTT) is a neurodevelopmental disorder caused primarily by de novo mutations (DNMs) in MECP2 and sometimes in CDKL5 and FOXG1. However, some RTT cases lack mutations in these genes. METHODS: Twenty-two RTT cases without apparent MECP2, CDKL5, and FOXG1 mutations were subjected to both whole exome sequencing and single nucleotide polymorphism array-based copy number variant (CNV) analyses. RESULTS: Three cases had MECP2 mutations initially missed by clinical testing. Of the remaining 19 cases, 17 (89.5%) had 29 other likely pathogenic intragenic mutations and/or CNVs (10 cases had two or more). Interestingly, 13 cases had mutations in a gene/region previously reported in other NDDs, thereby providing a potential diagnostic yield of 68.4%. These mutations were significantly enriched in chromatin regulators (corrected p = 0.0068) and moderately in postsynaptic cell membrane molecules (corrected p = 0.076) implicating glutamate receptor signaling. CONCLUSION: The genetic etiology of RTT without MECP2, CDKL5, and FOXG1 mutations is heterogeneous, overlaps with other NDDs, and complex due to high mutation burden. Dysregulation of chromatin structure and abnormal excitatory synaptic signaling may form two common pathological bases of RTT. |
format | Online Article Text |
id | pubmed-5107176 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
record_format | MEDLINE/PubMed |
spelling | pubmed-51071762017-01-11 Enrichment of mutations in chromatin regulators in people with Rett Syndrome lacking mutations in MECP2 Sajan, Samin A. Jhangiani, Shalini N. Muzny, Donna M. Gibbs, Richard A. Lupski, James R. Glaze, Daniel G. Kaufmann, Walter E. Skinner, Steven A. Anese, Fran Friez, Michael J. Jane, Lane Percy, Alan K. Neul, Jeffrey L. Genet Med Article PURPOSE: Rett Syndrome (RTT) is a neurodevelopmental disorder caused primarily by de novo mutations (DNMs) in MECP2 and sometimes in CDKL5 and FOXG1. However, some RTT cases lack mutations in these genes. METHODS: Twenty-two RTT cases without apparent MECP2, CDKL5, and FOXG1 mutations were subjected to both whole exome sequencing and single nucleotide polymorphism array-based copy number variant (CNV) analyses. RESULTS: Three cases had MECP2 mutations initially missed by clinical testing. Of the remaining 19 cases, 17 (89.5%) had 29 other likely pathogenic intragenic mutations and/or CNVs (10 cases had two or more). Interestingly, 13 cases had mutations in a gene/region previously reported in other NDDs, thereby providing a potential diagnostic yield of 68.4%. These mutations were significantly enriched in chromatin regulators (corrected p = 0.0068) and moderately in postsynaptic cell membrane molecules (corrected p = 0.076) implicating glutamate receptor signaling. CONCLUSION: The genetic etiology of RTT without MECP2, CDKL5, and FOXG1 mutations is heterogeneous, overlaps with other NDDs, and complex due to high mutation burden. Dysregulation of chromatin structure and abnormal excitatory synaptic signaling may form two common pathological bases of RTT. 2016-05-12 2017-01 /pmc/articles/PMC5107176/ /pubmed/27171548 http://dx.doi.org/10.1038/gim.2016.42 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Sajan, Samin A. Jhangiani, Shalini N. Muzny, Donna M. Gibbs, Richard A. Lupski, James R. Glaze, Daniel G. Kaufmann, Walter E. Skinner, Steven A. Anese, Fran Friez, Michael J. Jane, Lane Percy, Alan K. Neul, Jeffrey L. Enrichment of mutations in chromatin regulators in people with Rett Syndrome lacking mutations in MECP2 |
title | Enrichment of mutations in chromatin regulators in people with Rett Syndrome lacking mutations in MECP2 |
title_full | Enrichment of mutations in chromatin regulators in people with Rett Syndrome lacking mutations in MECP2 |
title_fullStr | Enrichment of mutations in chromatin regulators in people with Rett Syndrome lacking mutations in MECP2 |
title_full_unstemmed | Enrichment of mutations in chromatin regulators in people with Rett Syndrome lacking mutations in MECP2 |
title_short | Enrichment of mutations in chromatin regulators in people with Rett Syndrome lacking mutations in MECP2 |
title_sort | enrichment of mutations in chromatin regulators in people with rett syndrome lacking mutations in mecp2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107176/ https://www.ncbi.nlm.nih.gov/pubmed/27171548 http://dx.doi.org/10.1038/gim.2016.42 |
work_keys_str_mv | AT sajansamina enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2 AT jhangianishalinin enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2 AT muznydonnam enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2 AT gibbsricharda enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2 AT lupskijamesr enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2 AT glazedanielg enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2 AT kaufmannwaltere enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2 AT skinnerstevena enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2 AT anesefran enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2 AT friezmichaelj enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2 AT janelane enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2 AT percyalank enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2 AT neuljeffreyl enrichmentofmutationsinchromatinregulatorsinpeoplewithrettsyndromelackingmutationsinmecp2 |